|1.||Zimmerman, Richard K: 9 articles (11/2014 - 01/2004)|
|2.||Nowalk, Mary Patricia: 8 articles (11/2014 - 01/2004)|
|3.||Vila-Corcoles, Angel: 6 articles (04/2014 - 04/2008)|
|4.||Raymund, Mahlon: 6 articles (09/2012 - 01/2004)|
|5.||Esposito, Susanna: 5 articles (06/2015 - 11/2007)|
|6.||Oishi, Kazunori: 5 articles (06/2014 - 01/2010)|
|7.||Ochoa-Gondar, Olga: 5 articles (04/2014 - 04/2008)|
|8.||Dey, Aditi: 5 articles (12/2013 - 09/2010)|
|9.||Klugman, Keith P: 5 articles (10/2013 - 03/2007)|
|10.||Nahm, Moon H: 5 articles (09/2012 - 01/2008)|
12/01/1993 - "The efficacy of pneumococcal vaccines in preventing non-bacteremic pneumonia in high-risk subjects, however, has not been proven. "
07/01/2007 - "The flu and pneumococcal vaccines provide some protection against it, but pneumonia is still a major cause of death."
07/01/2008 - "Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?"
01/01/2015 - "An unconjugated 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been available for decades; however data on protection against pneumonia are inconsistent. "
06/16/2008 - "This conference provided substantial insight into many facets of pneumonia prevention as well as addressing the overarching question: What are the characteristics of pneumococcal vaccines that are associated with protection against pneumonia?"
12/01/1993 - "Pneumococcal vaccines have been proven to be effective in preventing the invasive complications of S pneumoniae infection. "
10/01/2011 - "Conjugate pneumococcal vaccines offer suboptimal protection against mucosal infections and are restricted in serotype and geographical coverage. "
03/01/2000 - "In an open trial, we evaluated the immunogenicity and tolerance of a new 7-valent pneumococcal conjugate vaccine in 22 infection-prone nonresponders to pneumococcal polysaccharide vaccine and 21 controls. "
01/01/2015 - "The expanded coverage of newer polyvalent pneumococcal vaccines can probably prevent infections by serotypes 19A, 19F, 6B and 3."
01/01/2012 - "Recently introduced higher valency pneumococcal vaccines target the residual burden of invasive and non-invasive infections, including those caused by serotypes not included in PCV7. "
|3.||Human Influenza (Influenza)
03/01/1998 - "Even with the widespread availability and proven efficacy of influenza and pneumococcal vaccines, their use has remained suboptimal. "
04/01/2004 - "Within the first 6 months of free GMS care for all, the "new GMS" patients attended significantly more often than before with the percentage of high consulters increasing from 24% to 52% (p=0.0039), took more medications (from 1.72 to 2.2), showed improvement in all quality of care parameters (with the exception of PSA screening which remained static) and had improved attendance for influenza 40% to 62% (p=0.0277) and pneumococcal vaccines 2% to 26% (p=0.00054). "
06/01/2015 - "The interest of the method is illustrated by its application to two real life datasets: an HIV therapeutic vaccine trial (DALIA-1 trial), and data from a recent study on influenza and pneumococcal vaccines. "
05/01/2012 - "This study describes a mixed methods approach to examining physicians' beliefs and attitudes about and adoption of SOPs for adult immunizations, specifically, influenza and pneumococcal polysaccharide vaccine. "
04/03/2012 - "We performed a secondary analysis of data from the Mother's Gift project, a randomized study designed to test the effectiveness of inactivated influenza and pneumococcal vaccines during pregnancy. "
|4.||Chronic Obstructive Pulmonary Disease (COPD)
03/01/2008 - "The following discussion will examine the available data supporting pneumococcal polysaccharide vaccine use, the currently available laboratory methods to measure immunogenicity, and advances in the development of an improved pneumococcal vaccine that could better protect patients with COPD against this pathogen."
03/01/2006 - "A study was undertaken to evaluate the clinical efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPV) in immunocompetent patients with chronic obstructive pulmonary disease (COPD). "
12/01/2009 - "Over the past 15 years, no fewer than ten meta-analyses or systematic literature reviews of the efficacy of pneumococcal polysaccharide vaccine in adults have been conducted, including one specifically in chronic obstructive pulmonary disease patients. "
09/01/2012 - "Although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healthy persons, randomized controlled trials in chronic obstructive pulmonary disease (COPD) have demonstrated no benefit in the intention-to-treat population. "
03/01/2007 - "A study was undertaken to assess the antibody responses to a 23-valent pneumococcal polysaccharide vaccine and clinical outcome in Taiwanese patients with chronic obstructive pulmonary disease (COPD). "
04/01/2004 - "PnCRM-7 is more immunogenic than the polysaccharide pneumococcal vaccines and is 80-100% effective against vaccine-type invasive disease and 50-60% effective against vaccine-type pneumococcal otitis media. "
10/01/2007 - "Pneumococcal vaccines may be effective in preventing or decreasing the burden of disease related to otitis media. "
03/01/1981 - "Efficacy of pneumococcal polysaccharide vaccine in preventing acute otitis media in infants in Huntsville, Alabama."
05/01/2004 - "The objective of the present study was to analyse the prevalence of Streptococcus pneumoniae serotypes in children suffering from acute otitis media or invasive pneumococcal disease and to compare a coverage of serotypes by individual pneumococcal vaccines. "
02/20/1997 - "Conjugate pneumococcal vaccines are now in large scale efficacy trials, with outcomes of bacteraemia (California) and otitis media (Finland). "
|4.||Immunoglobulin G (IgG)
|6.||DNA (Deoxyribonucleic Acid)
|7.||Adrenal Cortex Hormones (Corticosteroids)
|9.||Anti-Bacterial Agents (Antibiotics)
|4.||Patient-Controlled Analgesia (Analgesia, Patient Controlled)